Eliem Concludes Patient Enrolment In Mid-Stage Study Of Radicular Back Pain Drug

Eliem Therapeutics ELYM has completed dosing of the last patient in its Phase 2a trial of ETX-810 in patients with chronic lumbosacral radicular pain (LSRP).

During the Phase 2a proof-of-concept trial evaluating ETX-810 inchronic lumbosacral radicular pain (LSRP), 149 patients are enrolled at sites across the United States.

Bob Azelby, Eliem's president and chief executive officer, said, "We are pleased to announce that we have dosed the last patient in our Phase 2a clinical trial evaluating ETX-810 in patients with LSRP, which is a large, underserved market where a significant percentage of patients treated with standard of care are inadequately relieved of their pain.”

LSRP is a neuropathic pain syndrome caused by compression, inflammation and/or injury of spinal nerve roots in the lower back and is characterized by lower back pain that radiates into the leg.

The company is planning to report topline clinical data from the Phase 2a trail in the third quarter of 2022 and an investor event ahead of the data to discuss the opportunity for ETX-810 for the treatment of LSRP.

Eliem Therapeutics Shares are trading high 2 percent At $3.97 during after-hour session.

Posted In: Study ConcludedBiotechPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.